En excerpt from the book :
"ALTERNATIVES IN CANCER THERAPY"
by Ross, R.Ph. Pelton, Lee Overholser
New from $8.95
Used from $1.95
SOME PEOPLE believe 714-X is a highly promising, nontoxic treatment for cancer, AIDS, and other immunodeficiency diseases. Others consider its developer, the French-born Canadian researcher Gaston Naessens, an opportunist with false credentials. His story is certainly one of the most interesting and controversial connected with alternative cancer treatments.
714-X does not have traditional journal-published scientific research to support the claims being made for it. However, it is used by thousands of people worldwide and is receiving such widespread attention that it deserves to be discussed.
Gaston Naessens was born in France in 1924. He received his university education in physics, biology, and chemistry during World War II at the Union Scientifique Nationale in Nice, France. Because of wartime conditions, Naessens was awarded a diploma that was the equivalent of a Ph.D. Due to a frustrating oversight, he did not petition Charles de Gaulle's new French government for an equivalency diploma after the war, so many of his detractors claim that he doesn't even have an academic degree.
Naessens believes, as do many other scientists, that some cells in the body develop cancerous characteristics every day. He calls this the initiation or cancerization phase of cancer; a healthy immune system is capable of recognizing and eliminating these potentially dangerous cells.
If the immune system is ineffective, the cells developed in the initiation phase continue to grow, and enter what Naessens refers to as the promotion or cocancerization phase of cancer development. Eventually the cells of the promotion phase reach a critical mass point and form a tumor.
According to Naessens, the fermentative metabolism of cancer cells requires high levels of nitrogen. He calls cancer cells nitrogen traps. He contends that during this phase the cancer cells begin to emit a substance that protects them from the immune system and enables them to extract nitrogen derivatives from the host. He calls this substance cocancerogenic K factor, or CKF.
Therapies and Trials
Naessens has developed several different therapies to strengthen the immune system to treat diseases such as cancer and AIDS. During the 1940s, he developed an anticancer product designed to interfere with the anaerobic fermentation characteristic of cancer metabolism. He named this product GN-24 (for the initials of his name and 1924, the year of his birth). The product was sold commercially through pharmacies, and some patients reported good results with various forms of cancer.
During the late 1950s, Naessens developed an immune-system-enhancing serum called Anablast by injecting cancer cells into a draft horse. Naessens contended that the animal produced antibodies for cancer and that the purified antibodies in this new serum were more effective than the previously developed GN-24 in the treatment of cancer and various forms of leukemia.
There are many anecdotal accounts of apparent cancer cures reported in the articles and books that have chronicled Naessens's
career, but no controlled clinical studies. The increasing popularity of Naessens's treatments led the French medical authorities to arrest and try him twice, once for the illegal practice of medicine and a second time for the illegal practice of pharmacy. Both times he was heavily fined, his laboratory closed, and most of his equipment confiscated.
He moved his laboratory to the island of Corsica, but again media stories drew hundreds of desperate patients to him, resulting in another trial. This time he was acquitted. Ultimately his legal difficulties caused him to emigrate in 1964 to Canada, where he hoped to continue his research with greater freedom.
Unfortunately, publicity over the death of a child receiving his treatment brought another trial, with accompanying worldwide media attention. The trial is covered in a book by the best-selling author Christopher Bird, in The Persecution and Trial of Gaston Naessens. (1)
Although the trials have been time consuming and difficult for Naessens, the testimony of his patients at his trials has brought worldwide attention to his therapies. The personal stories of many cancer patients during the Canadian trial are themselves fascinating. Patients who formerly had cancers of the stomach, intestines, kidney, liver, breast, brain, lymph glands, prostate gland, and larynx, and also leukemia, all testified in behalf of Naessens.
During the trial it was proved that the patient was already considered terminal before receiving treatment, that Naessens promoted 714-X only as an immune stimulant, not as a cure, and that he never promoted himself as a doctor nor charged for his services. Naessens was acquitted in this trial, which brought widespread attention to his 714-X cancer therapy.
Based on his theory of the development of cancer, Naessens developed a therapy designed to suppress CKF. He believes that if the CKF substance is neutralized, the immune system will be able to recognize cancer cells as foreign entities and attack them.
According to Naessens, he had discovered a derivative of
ordinary camphor that is capable of interfering with the formation of the CKF substance in cancer cells. He believes that CKF blocks the activity of leukocytes and other phagocytic cells, thus paralyzing the immune system's ability to respond. Naessens came up with the name 714-X for the new camphor compound by using his initials, G and N, which are the seventh and fourteenth letters of the alphabet, and the letter X, which is the twenty-fourth letter of the alphabet and stands for the year of his birth, 1924.
The 714-X is a derivative of camphor, with an extra nitrogen molecule attached. Supposedly 714-X supplies the body with the nitrogen it needs to neutralize the nitrogen-hungry tumorcells and stops cancer cells from producing CKF. Naessens believes that this enables the immune system to respond to the cancer.
The 714-X must be injected intralymphatically, usually into the lymphatic area in the groin. The 714-X vaporizes at body temperature, and will be absorbed by the lymph nodes in this area. Most doctors and nurses have not been trained to give intralymphatic injections. However, Naessens has taught patients how to locate the correct lymphatic area and successfully do their own injections.
The 714-X also contains organic salts, which are designed to change the consistency of the lymphatic fluid and enhance the lymphatic system's ability to carry away the toxins that are produced by cancer or other degenerative disease conditions.
One of the most impressive aspects of Gaston Naessens and his 714-X therapy is the number of documented successes with cancer patients that are on record. Unfortunately anecdotal evidence does not meet the rigorous double-blind, controlled studies required by medical and scientific authorities.
Many cancer patients who have been on their deathbed are now alive and healthy because Naessens made 714-X available to them. Many of these case histories are part of court records, since grateful patients have come forward in large numbers to testify in behalf of Naessens during his various court trials.
Several physicians have reported the successful use of 714-X
in treating cancer patients. One of them, Florianne Piers, is a medical doctor from Belgium who went to Canada to support Naessens during one of his trials. Piers treated seven cancer patients over a four-month period and reported, "The product prolonged the lives and eased the deaths of two terminally afflicted patients and has allowed the other five, who came to me with seriously advanced cancerous states, to see every one of their symptoms disappear and to take up their lives as if they had never incurred the disease." (1)
On June 8 and 9,1991, an international symposium on Gaston Naessens's work was held. Over 150 scientists from many different fields converged on the small town of Sherbrooke, Quebec, Canada, to study the application of714-X in treating cancer and to review case studies. The conference stimulated international interest in 714-X, so more physicians around the world are now experimenting with its use for their cancer patients.
According to Naessens, no contraindications for 714-X are known. Literature accompanying the product states that 714-X is nontoxic and that there are no known side effects. The protocol for administration of714-X states that vitamin E and
Bshould not be used simultaneously with 714-X.
The serum is injected daily via the lymphatic system, preferably into the right inguinal lymph node. The injection must be given very slowly, at the rate of 0.5 ml in fifteen to twenty minutes.
Initially, three series of twenty-one injections are required. The injections are given at the rate of one a day according to the following schedule:
| Fifth to twenty-first day
|| 0.50 ml
There is a period of three days of rest between each series. This is followed with booster shots according to the need of
the patient. Information on obtaining 714-X is given in the appendix.